OLIVEIRA, ERICA A. deFAINTUCH, BLUMA L.TARGINO, ROSELAINE C.MORO, ANA M.MARTINEZ, RAQUEL C.R.PAGANO, ROSANA L.FONOFF, ERICH T.CARNEIRO, CAMILA de G.GARCEZ, ALEXANDRE T.FARIA, DANIELE de P.BUCHPIGUEL, CARLOS A.2017-08-142017-08-142016OLIVEIRA, ERICA A. de; FAINTUCH, BLUMA L.; TARGINO, ROSELAINE C.; MORO, ANA M.; MARTINEZ, RAQUEL C.R.; PAGANO, ROSANA L.; FONOFF, ERICH T.; CARNEIRO, CAMILA de G.; GARCEZ, ALEXANDRE T.; FARIA, DANIELE de P.; BUCHPIGUEL, CARLOS A. Evaluation of GX1 and RGD‑GX1 peptides as new radiotracers for angiogenesis evaluation in experimental glioma models. <b>Amino Acids</b>, v. 48, n. 3, p. 821-831, 2016. DOI: <a href="https://dx.doi.org/10.1007/s00726-015-2130-y">10.1007/s00726-015-2130-y</a>. Disponível em: http://repositorio.ipen.br/handle/123456789/27701.0939-4451http://repositorio.ipen.br/handle/123456789/27701Gliomas are the most common type among all central nervous system tumors. The aggressiveness of gliomas is correlated with the level of angiogenesis and is often associated with prognosis. The aim of this study is to evaluate the novel GX1 peptide and the heterodimer RGD-GX1 radiolabeled with technetium-99m, for angiogenesis detection in glioma models. Radiolabeling and radiochemical controls were assessed for both radioconjugates. In vitro binding studies in glioma tumor cells were performed, as well as biodistribution in SCID mice bearing tumor cells, in order to evaluate the biological behavior and tumor uptake of the radiocomplexes. Blocking and imaging studies were also conducted. MicroSPECT/ CT images were acquired in animals with experimentally implanted intracranial tumor. Open field activity was performed to evaluate behavior, as well as perfusion and histology analysis. The radiochemical purity of both radiotracers was greater than 96 %. In vitro binding studies revealed rather similar binding profile for each molecule. The highest binding was for RGD-GX1 peptide at 120 min in U87MG cells (1.14 ± 0.35 %). Tumor uptake was also favorable for RGD-GX1 peptide in U87MG cells, reaching 2.96 ± 0.70 % at 1 h p.i. with 47 % of blocking. Imaging studies also indicated better visualization for RGD-GX1 peptide in U87MG cells. Behavior evaluation pointed brain damage and histology studies confirmed actual tumor in the uptake site. The results with the angiogenesis seeking molecule 99mTc-HYNIC-E- [c(RGDfk)-c(GX1)] were successful, and better than with 99mTc-HYNIC-PEG4-c(GX1). Future studies targeting angiogenesis in other glioma and nonglioma tumor models are recommended.821-831openAccesstumor cellsgliomastechnetium 99angiogenesispeptidesglucagonArtigo de periódico34810.1007/s00726-015-2130-y58.45